ES8501413A1 - Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl. - Google Patents

Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Info

Publication number
ES8501413A1
ES8501413A1 ES525361A ES525361A ES8501413A1 ES 8501413 A1 ES8501413 A1 ES 8501413A1 ES 525361 A ES525361 A ES 525361A ES 525361 A ES525361 A ES 525361A ES 8501413 A1 ES8501413 A1 ES 8501413A1
Authority
ES
Spain
Prior art keywords
inactivator
prepare
procedure
containing protein
protein called
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES525361A
Other languages
English (en)
Other versions
ES525361A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES8501413A1 publication Critical patent/ES8501413A1/es
Publication of ES525361A0 publication Critical patent/ES525361A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005—Stabilisers against oxidation, heat, light, ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A61L2103/09—Blood or products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UN MEDICAMENTO SEGURO CONTRA HEPATITIS QUE CONTIENE LA PROTEINA LLAMADA INACTIVADOR CL.CONSISTE EN A) CALENTAR A UNA TEMPERATURA DE 60JC DURANTE 10 HORAS Y EN PRESENCIA DE ESTABILIZADORES COMO AMINOACIDOS, AZUCARES, Y/O AZUCARES-ALCOHOLES, UNA SOLUCION QUE CONTIENE INACTIVADOR CL, PARA OBTENER UNA SOLUCION PREVIAMENTE PURIFICADA, AL PERDER SU INFECCIONIDAD SEGUN EL CONTENIDO DE VIRUS DE HEPATITIS B PRESENTE EN ELLA, B) TRATAR A LA SOLUCION DE LA ETAPA A) CON UN ADSORBENTE CON RADICALES HIDROFOBOS, A-B-ARO COMO PHENYL-SEPHAROSE(R) CL-4B PARA ELIMINAR A PH ENTRE 6 Y 9, LOS ESTABILIZADORES E IMPUREZAS QUE ACOMPAN/AN AL INACTIVADOR EN LA SOLUCION DE LA ETAPA A) Y OBTENER UNA SOLUCION DE INACTIVADOR CL PURIFICADA. DONDE A ES SEPHAROSE(R), B ES UN GRUPO FENILO Y ARO UN GRUPO AROMATICO Y C) AN/ADIR A LA SOLUCION DE LA ETAPA (B), UNA SAL NEUTRA PARA PRECIPITAR AL INACTIVADOR CL Y RECOGERLO CON UNA SOLUCION ACUOSA DE UNA SAL NEUTRA, PARA CONCENTRARLO.
ES525361A 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl. Granted ES525361A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung

Publications (2)

Publication Number Publication Date
ES8501413A1 true ES8501413A1 (es) 1984-11-16
ES525361A0 ES525361A0 (es) 1984-11-16

Family

ID=6169724

Family Applications (2)

Application Number Title Priority Date Filing Date
ES524511A Granted ES524511A0 (es) 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento
ES525361A Granted ES525361A0 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES524511A Granted ES524511A0 (es) 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento

Country Status (9)

Country Link
US (1) US4915945A (es)
EP (1) EP0101935B1 (es)
JP (2) JPS5944320A (es)
AT (1) ATE19590T1 (es)
AU (1) AU564614B2 (es)
CA (1) CA1223201A (es)
DE (2) DE3228502A1 (es)
ES (2) ES524511A0 (es)
ZA (1) ZA835561B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376367B (de) * 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
FR2618784B1 (fr) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
JP2729484B2 (ja) * 1988-04-28 1998-03-18 株式会社ミドリ十字 アンチトロンビン−▲ｉｉｉ▼の精製方法
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
EP0716611B1 (en) * 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2013093027A1 (en) 2011-12-22 2013-06-27 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
AU2017316513A1 (en) 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
CA3061279A1 (en) 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
AU2019361252A1 (en) 2018-10-17 2021-06-03 Csl Behring Gmbh Process for purifying C1-INH
CN114096558B (zh) 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322139B2 (es) * 1973-11-15 1978-07-06
NL7602846A (nl) * 1976-03-18 1977-09-20 Leuven Res & Dev Vzw Antiplasmine en een antiserum daartegen.
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution

Also Published As

Publication number Publication date
JPH07103044B2 (ja) 1995-11-08
JPS5944320A (ja) 1984-03-12
DE3363395D1 (en) 1986-06-12
JPH05306236A (ja) 1993-11-19
EP0101935B1 (de) 1986-05-07
ZA835561B (en) 1984-03-28
JPH0480886B2 (es) 1992-12-21
AU1745183A (en) 1984-02-02
ES525361A0 (es) 1984-11-16
US4915945A (en) 1990-04-10
CA1223201A (en) 1987-06-23
ES8404372A1 (es) 1984-04-16
ATE19590T1 (de) 1986-05-15
AU564614B2 (en) 1987-08-20
ES524511A0 (es) 1984-04-16
EP0101935A1 (de) 1984-03-07
DE3228502A1 (de) 1984-02-02

Similar Documents

Publication Publication Date Title
ES525361A0 (es) Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.
DE3379644D1 (en) Adsorbent and process for preparing the same
NO154864C (no) Fremgangsmaate ved fremstilling av renset detoksifisert endotoksin.
GB1531558A (en) Compositions having affinity for hepatitis virus and method for hepatitis virus removal
DE3366494D1 (de) New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives
FI852522L (fi) Menetelmä tymopentiinianalogien valmistamiseksi
DE3363642D1 (en) Process for the preparation of protein hydrolysates
GB2118948B (en) Method for separation of hemoglobin a1c
ATE2090T1 (de) Verfahren zur herstellung eines plasminogenaktivators, so erhaltener aktivator und ihn enthaltendes arzneimittel.
ES8302710A1 (es) "un procedimiento para la recuperacion de estimulantes de xantina de su solucion acuosa".
AU6393686A (en) Process for preparing halogen magnesium alanate and use thereof
JPS5615215A (en) Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
ES8404183A1 (es) Un procedimiento para la preparacion de composiciones farmaceuticas orales de acido propionhidroxamico.
JPS5219900A (en) Method of processing radioactive waste liquor
DE3260844D1 (en) Process for separating the (r,s) racemate of cysteine
SE8305386D0 (sv) 15-cycloaliphatic derivatives of 13,14-didehydro-carboprostacyclins and process for their preparation
JPS5630993A (en) Manufacture of complement third ingredient from human blood plasma
AU554313B2 (en) Immobilized pepsin for removing blood immune complex and method for removing blood immune complex using immobilized pepsin
JPS5228991A (en) Process for purifying substances affinitive to hydrophobic groups
ATE17488T1 (de) Verfahren zur herstellung von cefoperazonnatrium.
DD209820A5 (de) Verfahren zur herstellung von 2,4 substituierten-1,2,3 - 2h-triazol-5-carbonsaeuren
ATE14575T1 (de) Verfahren zur herstellung von thioaethern.
JPS54101486A (en) Purification of urokinase
JPS5774088A (en) Purification of estrase
ES427232A1 (es) Un procedimiento para extraer y aislar del veneno de las serpientes el componente enzimatico.

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20040601